Tevogen Details AI Initiative

Tevogen Bio Inc. provided stockholders with an overview of its artificial intelligence initiative, Tevogen.AI™. It aims to integrate machine learning and predictive modeling into Tevogen Bio’s ExacTcell™ technology. This is expected to enhance target identification and pre-clinical processes, strengthen the Company’s pipeline of innovative immunotherapies, accelerate clinical timelines, and reduce development costs.

Tevogen.AI has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend beyond Tevogen Bio. Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI’s team of data scientists and engineers.

Tevogen CEO, Dr. Ryan Saadi, stated that Tevogen.AI’s vision extends beyond transforming how therapies are developed and is expected to make a meaningful impact across multiple sectors of healthcare. He also applauded the leadership team at Tevogen.AI and its strategic partners for their innovative efforts.

Strategic Partnerships

Microsoft provides AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes. Databricks supplies data engineering and analytics capabilities to refine Tevogen’s AI models and enhance predictive accuracy.

Proprietary Tevogen.AI Technology

PredicTcell™

These AI tools can accurately predict immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments. The PredicTcell platform performs in-silico predictions for candidate selection across multiple diseases and continually improves with each accurate prediction. To date, Tevogen.AI has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome.

AdapTcell™

These algorithms decode the interactions between human leukocyte antigens (HLA) and T cells. AdapTcell is expected to enhance Tevogen Bio’s understanding of immune responses and open new therapeutic avenues. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map. Tevogen.AI plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results.

Tevogen will continue providing updates on the progress of Tevogen.AI.